公开(公告)号：US20190175721A1

公开(公告)日：2019-06-13

申请号：US16258094

申请日：2019-01-25

申请人： Oregon Health & Science University ,  Sanofi Pasteur, Inc.

发明人： Ted Milburn Ross ,  Tim Alefantis ,  Donald Martin Carter, JR. ,  Christopher Austin Darby ,  Harold Kleanthous

IPC分类号： A61K39/145 ,  A61K39/12

摘要： The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.

公开(公告)号：US20190161519A1

公开(公告)日：2019-05-30

申请号：US16306346

申请日：2017-06-02

申请人： Sanofi Pasteur Inc.

发明人： Tod Strugnell ,  Eliud Oloo

IPC分类号： C07K14/11 ,  A61P31/16 ,  G16B15/30 ,  G16B15/20

摘要： The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered influenza B hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple influenza B viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.

公开(公告)号：US10118951B2

公开(公告)日：2018-11-06

申请号：US15536726

申请日：2015-12-18

申请人： Sanofi Pasteur

发明人： Régis Sodoyer ,  Isabelle Legastelois

IPC分类号： C07K14/195 ,  C07K14/705 ,  A61K39/00 ,  C07K14/00 ,  C07K14/46 ,  C07K14/005 ,  C12N15/62 ,  C07K19/00

摘要： The present invention relates to polymerized recombinant proteins, to recombinant nucleic acids coding for the polymerized recombinant proteins, to expression cassettes comprising the recombinant nucleic acids, to host cells transformed by the expression cassettes and to a method for multimerizing a recombinant protein. The polymerized proteins of the invention may be used in pharmaceutical or immunogenic compositions. In particular, the recombinant proteins may be antigens, antibodies or scaffolds. In particular, the polymerized recombinant protein may be an influenza haemagglutinin.

公开(公告)号：US20180273909A1

公开(公告)日：2018-09-27

申请号：US15761913

申请日：2016-09-19

申请人： Sanofi Pasteur Biologics, LLC

发明人： Sophia Tara MUNDLE

IPC分类号： C12N7/00 ,  A61K35/76 ,  A61K47/26 ,  B01D63/02 ,  B01D15/34 ,  B01D15/38 ,  B01D61/14 ,  B01D71/68

CPC分类号： C12N7/00 ,  A61K35/76 ,  A61K47/26 ,  B01D15/34 ,  B01D15/3847 ,  B01D61/145 ,  B01D63/02 ,  B01D71/68 ,  C12N2760/00021 ,  C12N2760/00051 ,  C12N2760/00064

摘要： Disclosed herein are methods for the purification of Respiratory Syncytial Virus (RSV) particles from a host cell culture comprising treating the host cell culture with an endonuclease, filtering the material to remove cellular debris and/or aggregated material, applying the material to a core bead chromatography resin, and recovering the purified RSV particles. Also disclosed herein are pharmaceutical compositions comprising purified RSV.

公开(公告)号：US20180193447A1

公开(公告)日：2018-07-12

申请号：US15740889

申请日：2016-07-01

申请人： SANOFI PASTEUR

发明人： Fernando Noriega ,  Betzana Zambrano ,  Nadia Tornieporth ,  Mélanie Saville ,  Eric Plennevaux ,  Mark Boaz ,  Thomas Papa

IPC分类号： A61K39/12

CPC分类号： A61K39/12 ,  A61K2039/522 ,  A61K2039/5254 ,  A61K2039/545 ,  A61K2039/70 ,  C07K14/1825 ,  C12N2770/24134 ,  C12N2770/24141 ,  C12N2770/24171 ,  Y02A50/386 ,  Y02A50/388

摘要： The present invention relates to a yellow fever (YF) vaccine for use in a method for inducing a protective immune response against yellow fever, wherein said method comprises concomitantly administering said yellow fever vaccine to a human subject together with a tetravalent dengue vaccine which comprises a live attenuated dengue virus of each of serotypes 1 to 4. This invention also pertains to a tetravalent dengue vaccine which comprises a live attenuated dengue virus of each of serotypes 1 to 4 for use in a method of inducing a protective immune response against yellow fever, wherein said method comprises concomitantly administering said tetravalent dengue vaccine to a human subject together with a yellow fever (YF) vaccine.

公开(公告)号：US20180177861A1

公开(公告)日：2018-06-28

申请号：US15738417

申请日：2016-06-23

申请人： Sanofi Pasteur, Inc.

发明人： Carlos DiazGranados ,  Andrew Dunning

IPC分类号： A61K39/145 ,  C12N7/00 ,  A61P29/00

CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/545 ,  A61K2039/70 ,  A61P29/00 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16134 ,  C12N2760/16234 ,  Y02A50/478

摘要： This application relates to the field of prevention of pneumonia by administration of a high-dose influenza vaccine.

公开(公告)号：US10006706B2

公开(公告)日：2018-06-26

申请号：US14348869

申请日：2012-10-04

申请人： Sanofi Pasteur SA

发明人： Bernhard Luy ,  Matthias Plitzko ,  Manfred Struschka

IPC分类号： F26B5/06

CPC分类号： F26B5/06 ,  F26B5/065

摘要： A process line (300) for the production of freeze-dried particles under closed conditions is provided, the process line comprising at least the following separate devices: a spray chamber (302) for droplet generation and freeze congealing of the liquid droplets to form particles, and a bulk freeze-dryer (304) for freeze drying the particles, wherein a transfer section (308) is provided for a product transfer from the spray chamber (302) to the freeze-dryer (304), for the production of the particles under end-to-end closed conditions each of the devices (302, 304) and of the transfer section (308) is separately adapted for closed operation, and the spray chamber (302) is adapted for separation of the liquid droplets from any cooling circuit.

公开(公告)号：US20180125960A1

公开(公告)日：2018-05-10

申请号：US15534441

申请日：2015-12-08

申请人： SANOFI PASTEUR

发明人： Nadège ARNAUD-BARBE ,  Geneviève RENAULD-MONGENIE ,  Bachra ROKBI

IPC分类号： A61K39/095 ,  C07K14/22 ,  A61K39/00

CPC分类号： A61K39/095 ,  A61K2039/575 ,  C07K14/22 ,  C07K2319/10 ,  C07K2319/21 ,  C07K2319/40 ,  C07K2319/50 ,  C12N9/52

摘要： The present invention relates to novel polypeptides derived from meningitis proteins, in particular auto-transporters of the subtilinase subclass, and their use in vaccines and vaccine compositions for the prevention and/or treatment of meningitis and meningococcal infections.

公开(公告)号：US20180110849A1

公开(公告)日：2018-04-26

申请号：US15573351

申请日：2016-05-14

申请人： Sanofi Pasteur, Inc.

发明人： Laurence Quemeneur ,  Patricia Pietrobon ,  Patricia Ladono-Hayes ,  Steven HAUSER

IPC分类号： A61K39/08

CPC分类号： A61K39/08 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/575

摘要： The disclosure relates to generally to the field of therapeutic and/or protective vaccination against Clostridium dificile (C. difficile). More specifically, it relates to methods for immunizing a host against C. difficile strains expressing C. difficile binary toxin (CDT) and strains not expressing CDT. These methods involve the administration to a host of an immunogenic composition comprising inactivated purified C. difficile Toxin A and purified Toxin B. The purified C. difficile toxins may be derived from a C. difficile strain that does not express CDT.

公开(公告)号：US20180000920A1

公开(公告)日：2018-01-04

申请号：US15632480

申请日：2017-06-26

申请人： Sanofi Pasteur Biologics, LLC

发明人： C. Russell MIDDAUGH ,  Richard FAHRNER ,  Peter CIARAMETARO

IPC分类号： A61K39/08 ,  A61K9/19 ,  A61K47/12 ,  A61K9/00 ,  A61K47/08 ,  A61K47/26 ,  A61K39/00

CPC分类号： A61K39/08 ,  A61K9/0019 ,  A61K9/19 ,  A61K39/00 ,  A61K47/08 ,  A61K47/12 ,  A61K47/26 ,  A61K2039/55505

摘要： This invention relates to compositions including Clostridium difficile toxins and/or toxoids and corresponding methods. The compositions of the invention include one or more excipients that increase stability and/or decrease aggregation of the toxins.